reduce basal insulin dose when starting glp-1 receptor agonist Initiation and Titration of in Primary Care: Barriers and Practical Solutions Recommendations issued in official package

Cryo-EM and molecular dynamics simulation analysis of peptide variants of GLP-1 and exendin-4 reveal distinct receptor conformers with unique modes of peptidereceptor engagement.

Larger randomized controlled trials with long-term follow-up are necessary to confirm these associations and evaluate the risk-benefit ratios

GLP-1 drugs like Ozempic and Mounjaro may offer real benefits for people with type 1 diabetes: less insulin, flatter CGM curves, and emerging evidence for heart and kidney protection.

A new deal may cut the cost of weight-loss drugs, but this UVA professor warns of potential long-term risks.

Albert, MBA, PharmD, JD, DASPL